Yhun Yhong Sheen Professor Emeritus
Research Record
- Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer Radiology and Oncology, 2022, v.56 no.2, 185-197
- Radiotherapy-induced oxidative stress and fibrosis in breast cancer are suppressed by vactosertib, a novel, orally bioavailable TGF-β/ALK5 inhibitor Scientific Reports, 2022, v.12 no.1, 16104
- How Does "Regulatory Practice" Create Discrepancies in Drug Label Information Between Asian and Western Countries? Different Label Information for Direct Oral Anticoagulants Approved in the United States, Europe, Korea, and Japan THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2019, v.53 no.2, 233-242
- Simultaneous Quantitative Determination of Nine Hallucinogenic NBOMe Derivatives in Human Plasma Using Liquid Chromatography Tandem Mass Spectrometry Mass Spectrometry Letters, 2019, v.10 no.1, 18~26
- Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells Cancer Science, 2016, 26 JAN 2016
- TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition Cellular Physiology and Biochemistry, 2016, v.38 no.2, 571-588
- TGF-β type i receptor kinase inhibitor EW-7197 suppresses cholestatic liver fibrosis by inhibiting HIF1α-induced epithelial mesenchymal transition Cellular Physiology and Biochemistry, 2016, v.38 no.2, 571-588
- Antitubercular activities of the novel synthesized 1,2,4-triazole derivatives Bulletin of the Korean Chemical Society, 2015, v.36 no.1, 43-51
- Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells Oncotarget, 2015, v.6 no.35, 37526-37543
- EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling Cellular and molecular life sciences : CMLS, 2015, v.72 no.10, 2023-2039
- Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type i receptor kinase Bioorganic and Medicinal Chemistry Letters, 2015, v.25 no.22, 5228-5231
- TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling Scientific Reports, 2015, v.5
- 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-beta type I receptor kinase BIOORGANIC & MEDICINAL CHEMISTRY, 2014, v.22 no.9, 2724-2732
- An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition Cancer Letters, 2014, v.351 no.1, 72-80
- Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin- 2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent Journal of Medicinal Chemistry, 2014, v.57 no.10, 4213-4238
- EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis Molecular Cancer Therapeutics, 2014, v.13 no.7, 1704-1716
Academic Background
University of Illinois at Urbana-Champaign Ph.D.(분자 및 통합생리학)